Currently there is no cure for AMN; however, there are some dietary treatments that patients are using to help alleviate some of the symptoms of the disease.

Patients also sometimes take a treatment consisting of a mixture of glycerol trioleate and glycerol trierucate, more commonly referred to as Lorenzo's Oil. This treatment is considered experimental by the FDA and can cost approximately $440 per month. Because of its experimental status, most insurance companies will not cover this treatment.

One biotechnology company working to develop a treatment for AMN is ReceptoPharm, Inc., a subsidiary of Nutra Pharma Corporation. The company has two leading products: RPI-MN and RPI-78M and has just received MHRA approval to begin Phase IIb human clinical trials for the treatment of AMN. To learn more about ReceptoPharm, please click here.

RPI-78M possesses several desirable properties as a drug:

• It lacks measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
• It displays no serious adverse side effects following years of investigations in humans and animals.
• It is extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
• It is easy to administer.
• RPI-78M can be administered orally-a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.